Company profilePharmaceutical#1115 of 1,318 in Pakistan✓ No DRAP alerts

Curem Healtcare

Pharmaceutical company · 2 brands · 3 molecules

Ranked #129 of 137 companies in Anti-Infectives

2 registered products 3 pharmaceutical brands 3 distinct molecules 0 DRAP alerts

Company overview

2
registered products
3
pharmaceutical brands
3
distinct molecules
2
therapeutic classes
0
DRAP alerts

Curem Healtcare is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 2 product registrations across 3 distinct molecules. Its portfolio is concentrated in Anti-Infectives and Cardiac Care. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Curem

2 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Cefixime1 brand
Amlodipine1 brand
Valsartan1 brand

Therapeutic classes

Anti-Infectives · 1Cardiac Care · 1

Conditions treated

General Infections · 1Hypertension · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid3 products · Rs 325 – Rs 501.06
Median across source: Rs 354.06

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HIGH - Q INTERNATIONAL holds 139 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAnastrozoleAprepitantArachis Oil
BOSCH PHARMACEUTICALS (PVT) LTD. holds 155 molecules not in this portfolio
AmikacinAmoxicillinAmoxicillin SodiumAmoxicillin …50Mg Clavulanic Acid 12.5 MgAmoxycillinAmpicillin
HELIX PHARMA (PRIVATE) LIMITED holds 112 molecules not in this portfolio
000 I.UAmylaseArtemetherArtesunateAscorbic AcidAspirin

Get the full profile for Curem

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.